CLINICAL_TRIALS
ClinicalTrials.gov record update
Phase I/IB Multi-center Study of Irreversible EGFR/HER2 Tyrosine Kinase Inhibitor Afatinib (BIBW 2992) in Combination With Capecitabine for Advanced Solid Tumors and Pancretico-Biliary Cancers
This page presents selected fields from the linked source record. It does not add a medical interpretation.
Record identity and dates
- Source
- ClinicalTrials.gov
- Source record ID
- NCT02451553
- Title field or adapter rule
- protocolSection.identificationModule.officialTitle
- Ingested At
- 2026-04-28T10:38:37.695128+00:00
- Published At
- 2022-06-07T00:00:00+00:00
- Record Updated At
- 2022-06-07
- Timestamp Basis
- source retrieval time was not retained by the feed adapter
- Date limitation
- source retrieval time was not retained by the feed adapter
Fields recorded by this source
- protocolSection.conditionsModule.conditions
["Advanced Malignant Solid Neoplasm", "Bile Duct Carcinoma", "Recurrent Malignant Solid Neoplasm", "Recurrent Pancreatic Carcinoma", "Stage III Pancreatic Cancer AJCC v6 and v7", "Stage IVA Pancreatic Cancer", "Stage IVB Pancreatic Cancer"]- protocolSection.statusModule.lastUpdatePostDateStruct.date
"2022-06-07"- protocolSection.identificationModule.nctId
"NCT02451553"- protocolSection.identificationModule.officialTitle
"Phase I/IB Multi-center Study of Irreversible EGFR/HER2 Tyrosine Kinase Inhibitor Afatinib (BIBW 2992) in Combination With Capecitabine for Advanced Solid Tumors and Pancretico-Biliary Cancers"- protocolSection.statusModule.overallStatus
"COMPLETED"- protocolSection.designModule.phases
["PHASE1"]- protocolSection.statusModule.resultsFirstPostDateStruct.date
""
Study condition terms
Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.
This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.